Evidence map›Paper›PMID 38953023›Full record

ArticleFrontiers in immunology2024

Anoikis resistance regulates immune infiltration and drug sensitivity in clear-cell renal cell carcinoma: insights from multi omics, single cell analysis and

Xiangyang Wen, Jian Hou, Tiantian Qi, Xiaobao Cheng, Guoqiang Liao, Shaohong Fang, Song Xiao, Longlong Qiu, Wanqing Wei

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Anoikis in cancer: molecular mechanisms, resistance, and therapeutic strategies.Apoptosis : an international journal on programmed cell death · 2026
    Review
  2. Anoikis: To Die or Not to Die?International journal of molecular sciences · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiangyang Wen *The Department of Surgery, Shenzhen Longgang Second People's Hospital, Shenzhen, China.
Jian Hou *Department of Urology, The University of Hongkong-Shenzhen Hospital, Shenzhen, China.
Tiantian Qi *Department of Bone & Joint Surgery, Peking University Shenzhen Hospital, Shenzhen, China.
Xiaobao Cheng *Department of Urology, The University of Hongkong-Shenzhen Hospital, Shenzhen, China.
Guoqiang LiaoThe Department of Surgery, Shenzhen Longgang Second People's Hospital, Shenzhen, China.
Shaohong FangThe Department of Surgery, Shenzhen Longgang Second People's Hospital, Shenzhen, China.
Song XiaoThe Department of Surgery, Shenzhen Longgang Second People's Hospital, Shenzhen, China.
Longlong QiuThe Department of Surgery, Shenzhen Longgang Second People's Hospital, Shenzhen, China.
Wanqing WeiDepartment of Urology, Lianshui People's Hospital of Kangda College Affiliated to Nanjing Medical University, Huaian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Anoikis is a form of programmed cell death essential for preventing cancer metastasis. In some solid cancer, anoikis resistance can facilitate tumor progression. However, this phenomenon is underexplored in clear-cell renal cell carcinoma (ccRCC). Methods: Using SVM machine learning, we identified core anoikis-related genes (ARGs) from ccRCC patient transcriptomic data. A LASSO Cox regression model stratified patients into risk groups, informing a prognostic model. GSVA and ssGSEA assessed immune infiltration, and single-cell analysis examined ARG expression across immune cells. Quantitative PCR and immunohistochemistry validated ARG expression differences between immune therapy responders and non-responders in ccRCC. Results: ARGs such as CCND1, CDKN3, PLK1, and BID were key in predicting ccRCC outcomes, linking higher risk with increased Treg infiltration and reduced M1 macrophage presence, indicating an immunosuppressive environment facilitated by anoikis resistance. Single-cell insights showed ARG enrichment in Tregs and dendritic cells, affecting immune checkpoints. Immunohistochemical analysis reveals that ARGs protein expression is markedly elevated in ccRCC tissues responsive to immunotherapy. Conclusion: This study establishes a novel anoikis resistance gene signature that predicts survival and immunotherapy response in ccRCC, suggesting that manipulating the immune environment through these ARGs could improve therapeutic strategies and prognostication in ccRCC.

Indexed as

AnoikisCarcinoma, Renal CellKidney NeoplasmsSingle-Cell AnalysisBiomarkers, TumorCell Line, TumorDrug Resistance, NeoplasmGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLymphocytes, Tumor-InfiltratingMaleMultiomicsPrognosisT-Lymphocytes, RegulatoryTranscriptomeBiomarkers, Tumoranoikisimmune microenvironmentprognosisrenal cell carcinomasignature

Identifiers

PMID38953023
PMCPMC11215044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.